UT MD Anderson researchers found the YAP1 protein is a potential biomarker and therapeutic target to overcome chemotherapy resistance in patients with small cell lung cancer.
Learn more: https://t.co/h2zIzeYlk6 #EndCancer
Proud to share our @theNCI#HTAN-supported GAME3D team at #AACR26, with 3 talks (@DrMingyaoLi@tae_hwang and me) and 3 posters. We use #Spatial multi-omics, 3D modeling, digital pathology and AI to study #GastricCancer evolution. Learn more about GAME3D: https://t.co/ROZ4Gjm3su
Radiation oncology is changing fast.
But radiation can still injure normal tissue.
An excellent review in @NEJM explains how modern RadOnc is reducing that risk:
-Precision planning
-Adaptive radiotherapy
-Biologic personalization
-AI-assisted treatment design
the goal is simple: maximize tumor control while protecting normal tissue
https://t.co/Kvj2WKgDKX @OncoAlert
MD Anderson researchers found novel tumor suppressor BATF2 can be silenced by factors in the tumor microenvironment, leading to a reduced immune response in five preclinical models of head and neck cancers: https://t.co/68yPgWjf45 #EndCancer
2/5 Clinically, 10 pts with RMC were treated; there were no confirmed responses, median PFS was ~1.4 months, and 5/10 met radiologic criteria for hyperprogression. Thus, for RMC immune checkpoint combination was not just ineffective; it could be harmful.
Some cancer patients at MD Anderson rely on blood and platelet donations as part of their treatment.
If you are able, consider making an appointment to donate blood at the MD Anderson Blood Bank. #WorldBloodDonorDay#EndCancer
Thanks to a generous $150 million gift from Kinder Foundation, we announce the launch of Kinder Children’s Cancer Center. This joint venture of UT MD Anderson and @TexasChildrens has a single mission: to #EndChildhoodCancer. https://t.co/QFBRpX3KKp #UTMDAnderson_TexasChildrens
Online Now: Spatial and multiomics analysis of human and mouse lung adenocarcinoma precursors reveals TIM-3 as a putative target for precancer interception https://t.co/AcqAnCyQln
Great morning back at #AcademicTuesday, lecturing our @MDAndersonNews oncology fellows on stage IV lung cancer management!
We discussed how to sequence therapies, the importance of shared decision-making, & the value of patient support. Thanks @KelseyPanMD for the invite!